Increased soluble HLA-DRB1 in B-cell acute lymphoblastic leukaemia
- Author:
Norfarazieda Hassan
;
Jasbir Singh Dhaliwal
;
Hishamshah Mohd Ibrahim
;
Raudhawati Osman
;
Siti-Zuleha Idris
;
Lee Le Jie
;
Maha Abdullah
- Publication Type:Journal Article
- Keywords:
Human leukocyte antigen (HLA);
acute lymphoblastic leukaemia (ALL);
soluble HLA
- From:The Malaysian Journal of Pathology
2015;37(2):83-90
- CountryMalaysia
- Language:English
-
Abstract:
Soluble HLA (sHLA) are potential tumour markers released in order to counter immune surveillance.
sHLA-class II is less known especially in acute lymphoblastic leukaemia (ALL). This study aimed
to investigate soluble, surface and allelic expression of HLA Class II (sHLA-DR) in B-cell ALL
patients and compare with soluble expression in normal individuals. A sandwich enzyme-linked
immunosorbent assay (ELISA) was developed to measure soluble HLA-DRB1 in plasma. Flow
cytometric analysis was performed to determine median fluorescence intensity in HLA-DR surface
expression. HLA-DNA typing by polymerase chain reaction, sequence specific oligonucleotides, PCRSSO
was performed to determine HLA-DRB1 type in ALL samples. Results showed sHLA-DRB1
(mean+SEM) was significantly increased (p=0.001) in plasma of ALL patients (0.260±0.057 μg/mL;
n=30) compared to healthy controls (0.051±0.007μg/mL; n=31) of Malay ethnicity. However, these
levels did not correlate with percentage or median fluorescence intensity of HLA-DR expressed on
leukemia blasts (CD19+CD34+/-CD45loHLA-DR+) or in the normal B cell population (CD19+CD34-
CD45hiHLA-DR+) of patients. No significant difference was observed in gender (male/female) or
age (paediatric/adult). Only a trend in reduced sHLA was observed in patients carrying HLA-DR04.
These results have to be validated with a larger number of samples.
- Full text:P020150915450074771273.pdf
